We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$704M
AUM Growth
+$37.8M
Cap. Flow
+$141M
Cap. Flow %
19.98%
Top 10 Hldgs %
44.68%
Holding
54
New
11
Increased
21
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
CNTX icon
Context Therapeutics
CNTX
+$25.4M
2
ZLAB icon
Zai Lab
ZLAB
+$22.2M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.8M
4
SRRK icon
Scholar Rock
SRRK
+$13.6M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$11.7M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$16.3M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15.4M
3
KALV
KalVista Pharmaceuticals
KALV
+$10.4M
4
VKTX icon
Viking Therapeutics
VKTX
+$7.66M
5
NTLA icon
Intellia Therapeutics
NTLA
+$5.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
51
Intellia Therapeutics
NTLA
$1.8B
– –
-267,557
Closed -$5.5M
RGNX icon
52
Regenxbio
RGNX
$638M
– –
-50,000
Closed -$525K
SLDB icon
53
Solid Biosciences
SLDB
$1.05B
– –
-11,518
Closed -$80.3K
VKTX icon
54
Viking Therapeutics
VKTX
$3.75B
– –
-120,982
Closed -$7.66M
1 2
3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2024 Portfolio in Review

As of Q4 2024, MPM BioImpact held 54 positions worth $704M, up 5.7% from $667M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

MPM BioImpact deployed $141M of net new capital in Q4 2024, opening 11 new positions and adding to 21 existing holdings. Its largest new stake was Context Therapeutics: 14,705,882 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $16.3M trimmed.

  • MPM BioImpact's largest Q4 2024 buy was Context Therapeutics: 14,705,882 shares worth $15.4M.
  • MPM BioImpact added most to PTC Therapeutics in Q4 2024, an estimated $14.8M increase.
  • MPM BioImpact's biggest Q4 2024 reduction was Insmed, cutting an estimated $16.3M.
  • MPM BioImpact fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $15.4M.
  • MPM BioImpact's ten largest holdings make up 45% of its $704M portfolio in Q4 2024.
  • MPM BioImpact opened 11 new positions and closed 7 in Q4 2024.
  • MPM BioImpact's portfolio value rose 5.7% quarter-over-quarter to $704M.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.